Follow Intuitive Surgical to never miss an important update.
Barclays set its price target for the robotic surgery leader at $485 on Tuesday. This is slightly above the $481 average target held by analysts who follow the company. While the firm did not change its overall rating, the new target reflects confidence that the stock can rise about 18 percent from where it trades today.
Source: Barclays
A new study covering 13 common medical conditions found that patients who had surgery with the da Vinci robot spent less time in the hospital and returned to work sooner than those who had open or laparoscopic surgery. Laparoscopic surgery is a traditional method where doctors use small incisions and hand-held tools rather than a robotic interface.
This is a win for the company because it provides concrete data that hospitals and insurance companies use to justify the high cost of robotic systems. When a robot can prove it gets patients home faster, it makes the machine a more attractive investment for hospitals looking to free up beds and reduce costs. For long-term owners, this reinforces the idea that robotic surgery is becoming the standard of care rather than an expensive alternative.
Source: GlobeNewsWire
Oppenheimer upgraded the stock to Outperform, which is their way of saying they expect it to do better than the broader market. This move comes while the stock is trading at about $372, significantly lower than the $491 average price target set by analysts across the industry.
This kind of upgrade from a major firm suggests growing confidence in the company's ability to roll out its new systems and grow its surgical volumes. For a long-term owner, it signals that professional analysts see the current price as a discount compared to the company's actual value.
HSBC lowered its rating on the company to hold, a neutral stance that suggests the stock may not have much room to rise in the near term. The firm set a price target of $391, which is significantly lower than the average analyst target of $491.
This move reflects a more cautious view on the company's valuation after it warned about potential changes in insurance plans that could affect demand for its surgical robots. While the business remains a leader in robotic surgery, analysts are weighing whether the current stock price already accounts for its future growth.
Source: HSBC
The company is collaborating with Deion "Coach Prime" Sanders to increase public awareness of robotic-assisted surgery. The goal is to help patients better understand the different options available to them when they need medical procedures. While this is a high-profile marketing move, it does not change the core business. It is a routine effort to keep the company's technology top-of-mind for patients who might otherwise choose traditional surgery.
Source: GlobeNewsWire
Management has beat its own profit targets for eight straight quarters. The business is consistently outrunning forecasts even as it grows at a double-digit pace.
| Expectation | |
|---|---|
| EPS | $2.65 |
| Revenue | $2.91B |
Follow Intuitive Surgical to get the latest and most important updates.
Follow ISRG